Stemline Therapeutics, Inc (STML) Covered Calls

Stemline Therapeutics, Inc covered calls Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.

You can sell covered calls on Stemline Therapeutics, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for STML (prices last updated Wed 4:16 PM ET):

Stemline Therapeutics, Inc (STML) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
10.86 +0.24 9.52 11.95 294K - 0.0B
Covered Calls For Stemline Therapeutics, Inc (STML)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 21 10 0.95 11.00 -9.1% -332.2%
Jan 18 10 1.35 10.60 -5.7% -54.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing proprietary therapeutics that target cancer stem cells. It currently developing two clinical stage products: SL-401 and SL-701, as well as a pipeline of preclinical candidates that include SL-801. The SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R, present on CSCs and tumor bulk of a variety of hematologic cancers. The SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. Stemline Therapeutics was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.